S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:COGT

Cogent Biosciences Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$7.93
+0.46 (+6.16 %)
(As of 03/5/2021 04:00 PM ET)
Add
Compare
Today's Range
$7.10
Now: $7.93
$7.93
50-Day Range N/A
52-Week Range
$2.20
Now: $7.93
$52.13
Volume719,229 shs
Average Volume300,550 shs
Market Capitalization$153.92 million
P/E RatioN/A
Dividend YieldN/A
Beta3.13
Unum Therapeutics Inc., a biopharmaceutical company, focuses on developing a pipeline of novel therapies to treat cancer patients. The company's novel proprietary technology, known as Bolt-On Chimeric Receptor (BOXR), is designed to improve the functionality of engineered T cells by discovering and incorporating a Â'bolt-on' transgene into a patients' engineered T cells to overcome resistance of the solid tumor microenvironment to T cell attack. Its advanced program, PLX9486, is a selective KIT D816V inhibitor that is being developed to treat patients with systemic mastocytosis and gastrointestinal stromal tumors. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Cogent Biosciences logo

Headlines

Cogent Biosciences Inc
December 19, 2020 |  bloomberg.com
Cogent Biosciences prices upsized $100M equity offering
December 2, 2020 |  seekingalpha.com
Cogent Biosciences EPS misses by $4.91
November 9, 2020 |  seekingalpha.com
Cogent Biosciences appoints Andrew Robbins as CEO
October 26, 2020 |  seekingalpha.com
Andy Frawley Appointed to cogint Board of Directors
March 27, 2020 |  www.bloomberg.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:COGT
CUSIPN/A
Phone561-757-4000
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.50 million
Book Value$4.14 per share

Profitability

Net Income$-31,830,000.00
Net Margins-264.14%

Miscellaneous

Market Cap$153.92 million
Next Earnings Date3/25/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.26 out of 5 stars

Medical Sector

824th out of 1,972 stocks

Pharmaceutical Preparations Industry

395th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Receive COGT News and Ratings via Email

Sign-up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cogent Biosciences (NASDAQ:COGT) Frequently Asked Questions

Is Cogent Biosciences a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cogent Biosciences in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cogent Biosciences stock.
View analyst ratings for Cogent Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Cogent Biosciences?

Wall Street analysts have given Cogent Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cogent Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Cogent Biosciences?

Cogent Biosciences saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 1,520,000 shares, an increase of 54.0% from the January 28th total of 987,300 shares. Based on an average trading volume of 488,800 shares, the short-interest ratio is presently 3.1 days. Approximately 2.6% of the company's shares are sold short.
View Cogent Biosciences' Short Interest
.

When is Cogent Biosciences' next earnings date?

Cogent Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, March 25th 2021.
View our earnings forecast for Cogent Biosciences
.

How were Cogent Biosciences' earnings last quarter?

Cogent Biosciences, Inc. (NASDAQ:COGT) issued its earnings results on Wednesday, November, 8th. The technology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.09. The technology company had revenue of $57.25 million for the quarter, compared to analysts' expectations of $62.24 million. Cogent Biosciences had a negative net margin of 264.14% and a negative trailing twelve-month return on equity of 100.89%. The company's quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.19) EPS.
View Cogent Biosciences' earnings history
.

What price target have analysts set for COGT?

5 analysts have issued 12 month price objectives for Cogent Biosciences' shares. Their forecasts range from $4.00 to $24.00. On average, they expect Cogent Biosciences' share price to reach $17.50 in the next year. This suggests a possible upside of 120.7% from the stock's current price.
View analysts' price targets for Cogent Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Cogent Biosciences' key executives?

Cogent Biosciences' management team includes the following people:
  • Mr. Andrew R. Robbins M.B.A., Pres, CEO & Director (Age 45)
  • Mr. John L. Green C.A., CPA, CFO & Principal Accounting Officer (Age 41)
  • Mr. Brad Barnett, Chief Technology Officer
  • Ms. Erin Schellhammer, Chief People Officer
  • Dr. Jessica Sachs M.D., Chief Medical Officer (Age 46)

Who are some of Cogent Biosciences' key competitors?

What other stocks do shareholders of Cogent Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cogent Biosciences investors own include Corbus Pharmaceuticals (CRBP), Visa (V), Viveve Medical (VIVE), Red Violet (RDVT), Freeport-McMoRan (FCX), HP (HPQ), Nutanix (NTNX), OPKO Health (OPK), STMicroelectronics (STM) and Actinium Pharmaceuticals (ATNM).

What is Cogent Biosciences' stock symbol?

Cogent Biosciences trades on the NASDAQ under the ticker symbol "COGT."

Who are Cogent Biosciences' major shareholders?

Cogent Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (8.91%), Ghost Tree Capital LLC (5.67%), Hillhouse Capital Advisors LTD. (5.15%), Morgan Stanley (4.79%), Atlas Venture Associates IX LLC (4.72%) and Orbimed Advisors LLC (3.37%).
View institutional ownership trends for Cogent Biosciences
.

Which major investors are buying Cogent Biosciences stock?

COGT stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Ghost Tree Capital LLC, Hillhouse Capital Advisors LTD., Morgan Stanley, Atlas Venture Associates IX LLC, Orbimed Advisors LLC, BlackRock Inc., and Samsara BioCapital LLC.
View insider buying and selling activity for Cogent Biosciences
or or view top insider-buying stocks.

What is Cogent Biosciences' stock price today?

One share of COGT stock can currently be purchased for approximately $7.93.

How much money does Cogent Biosciences make?

Cogent Biosciences has a market capitalization of $153.92 million and generates $22.50 million in revenue each year. The technology company earns $-31,830,000.00 in net income (profit) each year or ($4.16) on an earnings per share basis.

What is Cogent Biosciences' official website?

The official website for Cogent Biosciences is www.cogint.com.

Where are Cogent Biosciences' headquarters?

Cogent Biosciences is headquartered at 2650 NORTH MILITARY TRAIL SUITE 300, BOCA RATON FL, 33431.

How can I contact Cogent Biosciences?

Cogent Biosciences' mailing address is 2650 NORTH MILITARY TRAIL SUITE 300, BOCA RATON FL, 33431. The technology company can be reached via phone at 561-757-4000 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.